摘要
综述了他唑巴克坦/哌拉西林(TAZ/PIPC)的体外和体内抗菌作用、药代动力学及临床应用。他唑巴克坦是β-内酰胺酶抑制剂,TAZ与PIPC联合应用对各种产生β-内酰胺酶的细菌有协同抗菌作用。TAZ/PIPC对小鼠全身感染各种产酶细菌优于单用PIPC的效果。两药联合静注有良好药代动力学性能以及对各种实验动物未见明显药理影响,临床应用于各种感染性疾病,有效率为85.5%。
The in vitro and in vivo antibacterial activities,pharmacokinetics,general pharmacology and clinical use of a combined regimen of tazobactam/piperacillin(TAZ/PIPC)are reviewed.Tazobactam,a new β lactamase inhibitor,when combined with piperacillin shows a synergistic antibacterial activity with a more potent theraputic effect than single PIPC in mice with systemic infection of β lactamase producing strains.TAZ/PIPC has a promising pharmacokinetic property and no significant pharmacological effect on experimental animals.It has clinically a effective rate of 85.5% for various infections with rare side effects.
出处
《中国新药杂志》
CAS
CSCD
1996年第4期265-270,共6页
Chinese Journal of New Drugs
关键词
他唑巴克坦
哌拉西林
抗菌活性
药代动力学
Tazoboctam
Piperacillin
Antibacterial activity
Phamacokinetics
Clinical effect
Side reaction